PrecipioPRPO
Recorded

Precipio 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration36 minParticipants8

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Welcome to Precipio Q3 2026 shareholder update conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. Please note that the conference is being recorded. Statements made during this call contain forward-looking statements about our business. You should not place undue reliance on forward-looking statements as these statements are based upon our current expectations, forecasts, and assumptions, and are subject to significant risks and uncertainties. These statements may be identified by words such as may, will, should, could, expect, intend, plan, anticipate, believe, estimate, predict, potential, forecast, continue, or the negative of these terms or other words or terms of similar meaning.

Operator

Risks and uncertainties that could cause our actual results to differ materially from those set forth in any forward-looking statements include, but are not limited to, the matters listed under risk factors in our annual report on Form 10-K for the year ended December 31, 2025, which is on file with the Securities and Exchange Commission, as well as other risks detailed in our subsequent filings with the Securities and Exchange Commission. These reports are available at www.sec.gov. Statements and information, including forward-looking statements, speak only to the date they are provided, unless an earlier date is indicated, and we do not undertake any obligation to publicly update any statements or information, including forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Now let me hand the call over to Ilan Danieli, Precipio's CEO.

Ilan DanieliCEO

Please go ahead. Good afternoon, everyone, and thank you for joining us.

Ilan DanieliCEO

Before we jump into a review of the results for Q3 2026 and share several thoughts for 2027, I thought that as we come to the end of another successful year, it might be helpful to add another member of the management team to these calls. I would like to introduce my co-founder and Precipio's Chief Operating Officer, Zaki Sabet. Along with Dr. Ayman Mohamed, the three of us started Precipio in 2011, and we have been inseparable since. Prior to founding Precipio, Zaki spent his career in the diagnostics industry. While at college, Zaki worked as an accessioner during the night shift in a lab in New Jersey, and over the years, he moved up through the ranks of lab tech, then supervisor, to eventually manage the entire laboratory.

Ilan DanieliCEO

Bringing his in-depth expertise, Zaki was responsible for building what is today, to the best of our knowledge, at our size, one of the few profitable hematopathology laboratories in the country. At Precipio, Zaki oversees all company operations, including both our clinical laboratory, as well as operations for the Products Division, including manufacturing and supply chain. Today, Zaki will be joining me in sharing some remarks, and he will also be available to answer questions during the Q&A section. As this is our last scheduled shareholder call of 2026, I would like to put these results in the context of the progress we have made over the past couple of years and explain how that progress sets the stage for 2027. In 2025, our focus was on getting the company to a cash flow positive position.

Ilan DanieliCEO

We'd gone through several dilutive financings and decided that it was time for the company to stand on its own two feet and become financially independent. We set our eyes on reaching cash flow positive through a combination of revenue growth alongside significant operational efficiency improvements. At the end of 2025, we were there. Our company was cash flow positive, no longer dependent on outside capital in order to survive, and for the first time, we were able to respond to the calls from the various investment banks and hedge funds looking to provide capital to Precipio with a polite but clear, "No, thank you." I can tell you, as the person responsible for raising money to keep the lights on for 15 years, that was a wonderful moment.

Ilan DanieliCEO

The second goal in 2025 was to determine if the products we created and that were used in our own lab would be real value to other laboratories. We carefully explored this market by identifying target customers in several segments, which would serve as an indicator of market interest. This meant reaching a better understanding of which products in which configuration suited each segment. It meant continuously refining our sales presentation and value proposition to give the customer what they wanted, and also to determine which level of support was required by each customer.

Ilan DanieliCEO

While many investors have observed that our revenue in 2025 remained relatively flat, our learning experience was a critical step at that time and serves as an important foundation for us to determine the course for our sales team to efficiently target the market, for our R&D team to build the right product, and for our support team to be well-equipped to onboard our customers. At the end of 2025, we had accomplished two key tasks. First, financial independence, and second, a market understanding of our customers and our value proposition. In 2026, with a better understanding of our customer base, our products mix, and how we can best serve our customer, we set out to validate our go-to-market strategy, reaching customers via distribution.

Ilan DanieliCEO

One of the things we learned in 2025 and before was that in the laboratory space, getting in front of the customer and meeting the right decision-makers is really difficult. Post-COVID, if you didn't have a personal relationship, it was near impossible. We also learned that once we were in front of the decision-maker, we were quite successful in making the sale. How do we get that door open for us? The distributors hold an important role in this field. Working with the top four distributors in the industry, Thermo Fisher, Medline, McKesson, and Cardinal Health, we have learned the power of the 200-plus sales reps each of these distributors employ. These are armies of well-trained, experienced, and well-connected reps that have a long-established relationship with their customer, often spanning 10 to 15 years.

Ilan DanieliCEO

There is no amount of money that would enable us to replicate even a fraction of that sales force power, so we decided that distribution was the way to go. We also learned that each distributor is different, with different organizational structures, division of responsibilities between different reps, and organizational culture differences that dictate how best to interact with each distributor. in 2026, we set out to figure the recipe for success with each distributor. During this process, we also learned what were the internal skill sets we needed to develop within our commercial team to best apply each recipe with each distributor. As we stand now at the end of 2026, we feel we figured out most of what we set out to discover in terms of the recipe with each distributor.

Ilan DanieliCEO

That has led to some new hires in our commercial team and to a clear internal articulation of our go-to-market strategy via distribution. You've seen the gradual growth of the Products Division over the first three quarters of this year. While it's always nice to see the business grow, this is by no means satisfactory to us, nor it is a reflection of our planned growth trajectory going forward. Quite the contrary. 2027 will mark an important next phase in Precipio's evolution as we shift our focus from developing and validating our commercial strategy to accelerated growth. With the right products, a clear understanding of our target customers, an established distribution strategy, and the commercial infrastructure we're putting in place, we believe we now have the foundation to pursue a significantly higher rate of growth in our product business.

Ilan DanieliCEO

For the first time, we'd like to share with shareholders some specific financial objectives against which we intend to measure our progress. For our Products Division, we are targeting an annual revenue run rate exceeding $10 million by the end of 2027, compared with approximately $4 million annualized run rate based on our third quarter results of 2026. Our Pathology Services business will also remain an important part of our growth strategy. Beyond its role in supporting product development and clinical validation, it also continues to generate the majority of our operating cash flow. We intend to continue growing this business, targeting an annualized revenue run rate of approximately $30 million by the end of 2027. Together, these objectives represent a combined annualized revenue run rate exceeding $40 million by the end of 2027.

Ilan DanieliCEO

To be clear, these are targets for the annualized revenue run rate we aim to achieve as we exit 2027, rather than a forecast of total revenue recognized during the year. We believe achieving these objectives would represent a significant milestone for Precipio, demonstrating the scalability of our product business while strengthening the financial foundation that enables us to fund continuing growth, product innovation, and expansion into new diagnostic markets. We recognize that these are ambitious objectives, and delivering against them will require disciplined execution, but we believe the progress made over the past two years positions us well for this next phase of growth. Now, let's turn to a review of Q3. Total revenue increased from approximately $7 million in Q2 to $7.2 million in Q3. Pathology revenue was approximately $6.3 million, and product revenue exceeded, for the first time, $1 million a quarter, an exciting milestone.

Ilan DanieliCEO

Adjusted EBITDA was approximately $400,000, consistent with Q2. Our operating cash flow was approximately $600,000, compared with approximately $700,000 in the second quarter. Total cash increased by approximately half a million during Q3, bringing our quarter-end cash balance above $3.5 million, compared with approximately $2.2 million a year earlier. These results give us a stronger financial foundation. With the confidence of a consistently cash-flowing business, it is now time to shift the balance. While maintaining positive cash flow, we plan to shift our focus to significant accelerated revenue growth. Let us discuss how we plan to scale up for growth on the product side. 2026 was all about understanding the recipe for growth. As we discussed, we view distribution as the key source of scalability for our Products Division, and we wanted to understand how to best make that channel work before committing resources to broader commercial expansion.

Ilan DanieliCEO

We deliberately approached this with a relatively small commercial team and a measured level of spending. We wanted to refine the distributor model and our overall sales strategy before building a larger sales and marketing effort around them. The sequence was intentional, establish the approach, learn from execution, and then invest in scaling it. We now believe we have a much clearer understanding of that recipe and how to support it. Our ability to connect effectively with the distributor reps, arm them with information to get us a meeting, and proceed to build a pipeline, all give us confidence we are ready for the next stage. It is now time to shift our emphasis from developing the model and understanding the recipe to implementing and expanding its reach. In 2027, growth will be our central commercial priority.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day